Shi Pharma Group (01093.HK): New indication for Dovonex (Elettixakin hydrochloride liposome injection) approved for marketing.

Zhijing Financial News App, Sihuan Pharmaceutical Group (01093.HK) announced that the new indication of the liposomal injection of irinotecan hydrochloride developed by the group (trade name: Doanei) has been approved for marketing by the National Medical Products Administration of the People's Republic of China. The newly approved indication is for first-line treatment of metastatic pancreatic cancer patients in combination with oxaliplatin, fluorouracil (5-FU), and leucovorin (LV).